Achievements

Present ~ 2016

2019
Acquired the international standard ISO 9001 certification for a quality management system (QMS)
Received the Minister’s Award (Ministry of Science and ICT) as an institute of outstanding research note management
Completed phase-3 clinical trial on Fexuprazan, a next-generation drug for gastroesophageal reflux
Awarded by the government as an outstanding innovative pharmaceutical company
DWN12088, a new drug for pulmonary fibrosis, designated as an orphan drug by the USFDA
Urusa 300mg obtained indication for prevention of postgastrectomy cholelithiasis, being the first in the world
Officially launched Jeuveau, an internally developed botulinum toxin, in the US
Launched Olomax, a compound of three agents (olmesarta, rosuvastatin and amlopidine)
Phase-3 clinical trial result of Nabota in the US published in an SCI-grade international journal
DWN12088, a new drug for pulmonary fibrosis, selected for the inter-governmental support project
Internally developed botulinum toxin approved by USFDA, being the first in Asia
2018
Nabota obtained indication for eye wrinkles as the first botulinum toxin in Korea
DWP14012, a new drug for gastroesophageal reflux, selected for inter-governmental support project
2016
Completed construction of the Daewoong Bio Center
Meropenem Inj, an antibiotic, approved by the USFDA

2015 ~ 2011

2015
Olostar won the Technology Award for new drug development at the 16th Korea New Drug Award (KNDA)
Began joint development in the field of antibody through M&A with HanAll BioPharma
2014
Received a Prime Minister Citation in the science and technology category of the Korea New Growth Management Awards
Won the Technology Award for new drug development at the 15th Korea New Drug Award (KNDA)
Nabota selected as a World Class Product of Korea by the Ministry of Trade, Industry and Energy (MOTIE) and the Korea Trade-Investment Promotion Agency (KOTRA)
Released Nabota, a botulinum toxin, in Korea
Released Olostar, a new drug compound of olmesartan and rosuvastatin
2013
Won the 2013 Innovative Pharmaceutical Company Award
2012
Caretropin Pen won the 2011-2012 World Star Award
Selected for World Class 300, a global business development project
Selected as an Innovative Pharmaceutical Company
2011
Caretropin Inj. received the Minister’s Award (Ministry of Knowledge Economy)

2010 ~ 2001

2008
Easyef acquired the International Nonproprietary Name (INN) certified by the World Health Organization (WHO) as the first in the world
2005
CoenzymeQ10 won the Minister’s Award (Ministry of Health and Welfare) at the Outstanding Technology Contest of the Health Industry Technologies Exposition Korea
CoenzymeQ10 won the Jang Yong-shil Award
Released Luphere, an anticancer agent
2003
Succeeded in developing CoenzymeQ10, being the second in the world
Easyef Topical Solution won second prize at the Korea New Drug Award (Korea Drug Research Association: KNDA)
2002
Easyef Topical Solution awarded as one of 100 Outstanding Patented Products
2001
Released Easyef Topical Solution, Korea’s first new bio-pharmaceutical drug
Acquired the KT (Korea Good Technology) mark for Easyef

2000 ~ Founded

1997
Won Outstanding Achievement Award (Korean Intellectual Property Office) for the patented technology of Easyef
1987
Received the Iron Tower Order of Industrial Service Merit in the science and technology category on the 1st Science Day
Acquired the first genetic engineering patent in Korea
1983
Established Daewoong Central R&D Institute
1974
Established Subsidiary Pharmaceutical Research Center